Posted by Michael Wonder on 25 Apr 2019
Lilly to establish an access program for patients as it prepares to withdraw Lartruvo from the global market
25 April 2019 - Lilly is working to ensure current patients access to Lartruvo with limited interruption after it is withdrawn from the market
Eli Lilly today announced that the company has been working to facilitate the withdrawal of Lartruvo (olaratumab) from the market for the treatment of advanced soft tissue sarcoma.
Lilly's actions to withdraw Lartruvo from the market follow the failure of the Phase 3 ANNOUNCE clinical trial, in which Lartruvo did not improve survival for patients. Lilly is establishing a program to ensure current patients will have access to Lartruvo with limited interruption after it is withdrawn from the market. The program will be established as allowed by local country regulations.
